Navigation Links
Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
Date:10/18/2010

CARLSBAD, Calif., Oct. 18 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the appointment of Thomas G. Wiggans as Chairman of its Board of Directors. Mr. Wiggans brings to the role more than 30 years of experience in successfully developing and commercializing drugs with several notable successes in the dermatology field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development and commercialization of novel drugs for the amelioration of skin scarring and other fibrotic disorders.

"We are delighted to have Mr. Wiggans join Excaliard," commented Gordon Foulkes, President of Excaliard, and Managing Director of RiverVest Venture Partners. "Tom has successfully led dermatology companies, such as Connetics and Peplin, and his guidance in Excaliard's growth will be invaluable."

"Excaliard has made impressive clinical progress in advancing its lead product EXC-001 through three Phase II clinical studies in skin scarring," commented Mr. Wiggans. "I am looking forward to working with the Excaliard team to bring EXC-001 and the company's product pipeline forward."

In August 2010, Excaliard announced positive results from its Phase 2 clinical trial of EXC 001. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo at 12 weeks post surgery. The final analysis for this study will be conducted 24 weeks after surgery. The data for this study and two additional skin scarring Phase 2 studies will be available later in 2010.

Most recently Mr. Wiggans was Chairman of the Board of Directors and Chief Executive Officer of Peplin, Inc., which was acquired in 2009 by LEO Pharma of Copenhagen, Denmark. Prior to that, he served as CEO of Connetics Corporation from 1994 until 2006, when the company was acquired by Stiefel Laboratories. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to 1992, Mr. Wiggans served in various positions at Ares-Serono Group, a pharmaceutical company, including President of its U.S. pharmaceutical operations. Mr. Wiggans currently serves as a Director of Onyx Pharmaceuticals, Sangamo Biosciences and Somaxon Pharmaceuticals. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

About EXC 001

EXC 001 is a new generation antisense medicine that may interrupt the process of fibrosis by inhibiting a growth factor. Unsatisfactory skin scarring can be associated with virtually every surgical procedure, including elective, reconstructive, or emergency surgery, traumatic wounds, and various dermatologic conditions, such as hypertrophic scars and keloids. Prevention and treatment of unsatisfactory skin scarring is an important unmet medical need.

About Excaliard Pharmaceuticals

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. EXC 001 was co-discovered by Isis Pharmaceuticals  Inc., (Nasdaq: ISIS) and Excaliard, and licensed to Excaliard Pharmaceuticals.


'/>"/>
SOURCE Excaliard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Implantable Medical Devices ... over the next decade to reach approximately $54.28 billion by 2025 ... witnessing include 3D medical printing is expected to develop and find ...
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... 24, 2017   QR Pharma , Inc., ... novel therapies for the treatment of Alzheimer,s, Parkinson,s ... of four world-class key opinion leaders to its ... QR Pharma,s previous roster of impressive advisors in ... support the development of the breakthrough mechanism of ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, ... officially formed a distribution partnership with Byers Scientific & Manufacturing , a ... , Through the agreement, OMI Industries formulated a special version of Ecosorb® for ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical economic ... the Frank Hawkins Kenan Institute of Private Enterprise at the University ... makers identified concrete solutions at the “What’s Next, America?” conference at the Kenan ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, ... Kleyne, the nation’s foremost water advocate and host of the nationally syndicated The ... Voice America, once again welcomed one of her favorite guests and colleagues, Dr. ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
(Date:1/24/2017)... ... , ... “The Octagon of Spiritual Balances”: a guide for the Christian ... of published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, in ... education and a master degree in theology. , ““The Octagon of Spiritual Balances” exposes ...
Breaking Medicine News(10 mins):